Purification and Radioreceptor Assay of Insulin-Like Growth Factor in Human Serum
スポンサーリンク
概要
- 論文の詳細を見る
Insulin-like growth factor (IGF) is the genoric designation for serum polypeptides such as somatomedins, multiplication stimulating activity (MSA), and non suppressible insulin-like activity (NSILA), which possess both insulin-like activity and cell growth promoting activity. We have purified one of IGF's from human plasma and established radioreceptor assay (RRA) for this IGF. RRA for insulin, using human placental microsomal membranes, was used to detect insulin-like activity throughout the isolation procedure. The soluble fraction from an acid ethanol extract of Cohn fraction IV was chromatographed on G-75 sephadex in 1% formic acid. The insulin-like activity which binds to insulin receptor (ILA) migrated as a small molecule (Kav=0.56-0.70). The active fraction was subjected to isoelectric focusing. Three peaks of ILA were identified at the position of pH 5.2, 7.0 and 8.5. The major fraction (pI 8.5) designated as ILA-C was further purified by G-50 sephadex gel filtration in 1M acetic acid. The apparent molecular weight of purified ILA-C is around 6,000. ILA-C stimulated <SUP>14</SUP>C-glucose oxidation in rat epididymal fat cells. It also potently augmented <SUP>3</SUP>H-Thymidine incorporation into DNA of 3T3 cells. Thus ILA-C satisfies the characteristics of IGF, but the identification of ILA-C among known IGFs' is not clear at present.<BR>Subsequently RRA for ILA-C, utilizing human placental membrane as a receptor, was developped. Placental membrane fraction (100-200μg protein), <SUP>125</SUP>I-ILA-C (50,000cpm) and ILA-C standard or unknown serum in a total volume of 0.5ml were incubated for 16 hrs at 4°. The membrane-bound and the free labelled ILA-C were separated by centrifugation and the pellet was counted in a gamma scintilation counter. An arbitrary unit of ILA-C was expressed as μU/ml insulin equivalent as determined by RRA for insulin. The bound <SUP>125</SUP>I-ILA-C was displaced dosedependently by ILA-C between 0.5μU and 100μU per tube. The binding of labelled ILA-C to the receptor was inhibited partially by somatomedin A and MSA, but only minimally by insulin. Somatomedin B, epidermal growth factor, nerve growth factor, fibroblast growth factor or proinsulin were without effect. Addition 1 to 10μl of sera gave the displacement curve parallel to that obtained by the standard.<BR>Comparison of elution patters of ILA-C in human serum on G-50 sephadex at acidic and neutral pH suggests that ILA-C is associated with serum protein and the complex is dissociated by acid. The presence of binding protein in serum might disturb the assay. The dilution curve of native serum between 1μl and 10μl was parallel to that of acid-dissociated serum, and thus ILA-C can be quantitatively measured in native serum at neutral pH in the range between 1μl and 10μl. Therefore all the following assays were done at neutral pH using serum less than 1μl. The intra and inter-assay variences were 6.7% and 20.4%, respectedly.<BR>The RRA can measure the concentration of ILA-C in the sera of a variety of mammals. Serum concentrations of ILA-C in normal males and females were 575±46 (mean±SEM), 528±27, respectedly. ILA-C levels were high in acromegalics (3, 133±245) and low in hypopituitary patients (286±47). Administration of hGH to patients with GH deficiency elevated ILA-C levels significantly. In cases of anorexia nervosa, ILA-C levels were generally low but increased as the body weight returned to normal. Very low levels were also found in cord bloods and in patients with liver cirrhosis, whereas uremic patients had high levels. In patients with diabetes mellitus and hypoglycemia due to extrapancreatic tumor ILA-C levels were normal or low.<BR>In summary, ILA-C was purified from human plasma using RRA for insulin and sensitive RRA for ILA-C was established. The levels of ILA-C in the serum are under the regulation of GH, as well as nutritional and other factors.
- Japan Society of Clinical Chemistryの論文
著者
関連論文
- 経皮的ラジオ波焼灼療法(RFA)による組織像の経時的変化
- ナトリウムヨードシンポーター遺伝子変異によるヨード濃縮障害性甲状腺機能低下症の1例
- P-226 血中IGF-II高値を伴い低血糖発作を示した限局性胸膜中皮腫の1手術例
- ポリペプチドホルモンのinternalization (エンドサイト-シス)
- 下垂体機能低下症 (検査計画法--内分泌疾患)
- 血管炎によると思れれた脳梗塞を合併したHodgkin病の1例
- ステロイドが著効を呈したFabry病(angiokeratoma corporis diffusum)の初期の1例
- 著明な溶血性貧血,間質性腎炎,低γ-globulin血症を呈したphenacetin中毒症の1例
- 一卵性双生児の一方に下垂体性巨人症を他方に先端巨大症を発症した兄弟例
- Marfanoid Hypermobility Syndromeの多発した一家系
- 胸腺腫を合併した筋強直性ジストロフィーの1剖検例
- 高度の好酸球増多とLöfflers endocarditisを伴つた好酸球性肺炎の1例 播種性好酸球性膠原病とLöffler症候群の疾患概念の検討を含めて
- 肝外性閉塞性黄疸を初発症状としたヘパトームの1例胆管内発育したヘパトーム
- 身体半側萎縮症と部分てんかんを合併したpachygyriaの1例
- 薬剤・抗体のimmune complexを証明したジギトキシンによる血小板減少症の1例
- 偽白血球増加現象を伴つた本態性クリオグロブリン血症の1例
- α-Ketoglutarateを基質とした肝δ-aminolevurinicacid合成活性の異常高値を示したvariegate porphyriaの1例
- 糖尿病, Cruveilhier-Baumgarten症候群並びに肝性脳症を合併し,相互に興味ある関連の認められた肝硬変の1例
- (2)糖尿病診断における血中インスリン測定の意義
- 白血球減少症および巨大脾腫を伴つたバセドウ病の1例プロピルサイオウラシル誘発性のループス様症候群および自己免疫性好中球減少症の文献的考察
- 大脳辺縁系刺激の甲状腺ホルモン分泌機構に及ぼす影響
- 糖尿病に合併したgross hyperlipemiaとその成因にかんする検討
- 脱ヨード酵素活性の二次的低下を伴ったathyreotic hypothyroidismにおける内分泌・代謝にかんする検討
- 脂肪肝と高脂血症を伴った肺胞蛋白症の1例
- 2. ウサギ肝成長ホルモン受容体の性質
- 肝疾患におけるLecithin:Cholesterol Acyltransferase活性--特にHigh Density Lipoproteinコレステロ-ルとの関係
- 高脂血症における血漿アポリポ蛋白E濃度
- Purification and Radioreceptor Assay of Insulin-Like Growth Factor in Human Serum
- Radioreceptor Assay of Epidermal Growth Factor
- Clinical Significance of Determination of the Circulating Levels of Dehydroepiandrosterone Sulfate
- Insufficiency of Insulin Secretory Responses in Primary Diabetes
- タイトル無し
- Effect of Gastrointestinal Hormones (VIP, GIP, Substance P and Bombesin) infused intrapancreatically on Insulin and Glucagon Secretion in Dog
- SERIAL DETERMINATION OF SERUM GOT ISOZYME ACTIVITIES FOR THE EVALUATION OF ACUTE HEPATIC DAMAGE
- タイトル無し
- Receptor Assay